Adlai Nortye Biopharma Co., Ltd.
Clinical trials sponsored by Adlai Nortye Biopharma Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New cancer pill AN4005 enters first human tests Results expected Nov 2026 (estimated)
- New drug AN8025 tested in patients with advanced cancers Results expected Jul 2027 (estimated)
-
New drug AN8025 tested in patients with advanced cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called AN8025 in about 91 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Participants receive the drug in 3-week cycles and are closely moni…
Phase 1 • Sponsor: Adlai Nortye Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New pill targets Hard-to-Treat cancers with RAS gene flaw
Disease control Recruiting nowThis early-phase study tests an experimental pill, AN9025, in adults with advanced solid tumors that have a specific genetic change called a RAS mutation. The main goal is to find a safe dose and check for side effects. About 118 participants will take the drug daily or weekly an…
Phase 1 • Sponsor: Adlai Nortye Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New cancer pill AN4005 enters first human tests
Disease control Recruiting nowThis early-phase study tests a new experimental drug called AN4005 in about 31 people with advanced solid tumors or lymphoma that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Participants take the drug by mouth twice …
Phase 1 • Sponsor: Adlai Nortye Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC